Press Release Archive

12.12.2023

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

12.11.2023

FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B

12.09.2023

Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

12.08.2023

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma

12.05.2023

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

12.04.2023

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

12.01.2023

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

11.28.2023

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

11.21.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.16.2023

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

11.02.2023

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

11.02.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference